| DB ID | MyCo_5485 |
| Title | Analytical and Clinical Evaluation of the PathoNostics AsperGenius Assay for Detection of Invasive Aspergillosis and Resistance to Azole Antifungal Drugs during Testing of Serum Samples |
| Year | 2015 |
| PMID | 25903571 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The study was a performance assessment of the AsperGenius assay with an anonymous, retrospective case/control design and no impact on patient management and thus did not require ethical approval |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | ITS |
| Biomarker Full Name | Internal Transcribed Spacer |
| Biomarker Type | Diagnostic |
| Biomolecule | Gene |
| Geographical Location | UK |
| Cohort | For the analytical evaluations, serum samples were spiked with various concentrations of Aspergillus genomic DNA for extraction, following international recommendations. For the clinical study, 124 DNA extracts from 14 proven/probable invasive aspergillosis (IA) cases, 2 possible IA cases, and 33 controls were tested. |
| Cohort No. | 16 Patients and 33 Control |
| Age Group | 18-87 |
| P Value | None |
| Sensitivity | 0.786 |
| Specificity | 1 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | PCR |
| Analysis Method | PathoNostics AsperGenius species assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | PathoNostics AsperGenius species assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
